2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

CRD3874

CRD3874-SI is a STING agonist. CRD3874 is a synthetic drug that activates STING, and STING stimulates the immune system to kill cancer cells. In experiments on blood from humans, CRD3874 makes blood cells produce molecules responsible for anti-cancer activity. CRD3874 was tested in mice with cancers including leukemia, head and neck cancer, lung cancer, pancreatic cancer and sarcoma. In these mice, CRD3874 made tumors shrink or disappear, and some mice developed long-lasting immunity against cancer.

Trial Locations (1)

21201

University of Maryland, Baltimore, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER